Increased Efficacy Through Moderate Dose Escalation of Chemotherapy: Interim Report From the HD9 Randomized Trial for Advanced Hodgkin’s Disease

News
Article
OncologyONCOLOGY Vol 13 No 3
Volume 13
Issue 3

This report aims to assess the effect of increased drug dose on the efficacy and toxicity of the BEACOPP regimen with

 

This report aims to assess the effect of increased drug dose on the efficacy and toxicity of the BEACOPP regimen with granulocyte colony-stimulating factor (G-CSF [Neupogen]) support in advanced-stage Hodgkin’s disease. Patients between 15 and 65 years old, either in stages IIB/IIIA with risk factors or in stages IIIB/IV, were eligible.

Eight courses of chemotherapy were followed by local irradiation of initial bulky and residual disease. From February 1993 to April 1998, 1,200 patients were randomized between standard COPP/ABVD (cyclophosphamide, Oncovin [vincristine], procarbazine, and prednisone/Adriamycin [doxorubicin], bleomycin, vinblastine, and dacarbazine; arm A); baseline-dose BEACOPP (bleomycin, etoposide, Adriamycin, cyclophosphamide, Oncovin, procarbazine, and prednisone; arm B); and escalated-dose BEACOPP (arm C).

Baseline BEACOPP was approximately equivalent in dosage to COPP/ABVD but shortened to a 3-week course. Cyclophosphamide, etoposide, and doxorubicin were escalated to 192%, 200%, and 140% of baseline, respectively, and G-CSF was administered in arm C from day 8 until leukocyte recovery.

This third interim analysis, in February 1998, was restricted to patients randomized before August 1996. Median observation time was 27 months. A total of 689 patients (91%) were evaluable.

Acute toxicity (neutropenia, thrombopenia, anemia, infection) with BEACOPP was increased but manageable; toxic deaths were no more frequent than with COPP/ABVD.

CONCLUSION: We conclude that moderate dose escalation is feasible and increases efficacy. Leukemogenicity must be monitored.

Click here for Dr. Bruce Cheson’s commentary on this abstract.

Articles in this issue

WHO Declares Lymphatic Mapping to Be the Standard of Care for Melanoma
Rituximab: Phase II Retreatment Study in Patients With Low-Grade or Follicular Non-Hodgkin’s Lymphoma
Response Criteria for NHL: Importance of “Normal” Lymph Node Size and Correlations With Response
Chemotherapy Plus Radiation Improves Survival in Patients With Cervical Cancer
A Randomized Trial of Fludarabine, Mitoxantrone (FM) Versus Doxorubicin, Cyclophosphamide, Vindesine, Prednisone (CHEP) as First Line Treatment in Patients With Advanced Low-Grade Non-Hodgkin's Lymphoma: A Multicenter Study by GOELAMS Group
Navelbine Increased Elderly Lung Cancer Patients’ Survival
Fludarabine Versus Conventional CVP Chemotherapy in Newly C Diagnosed Patients With Stages III and IV Low-Grade Malignant Non-Hodgkin’s Lymphoma: Preliminary Results From a Prospective, Randomized Phase III Clinical Trial in 381 Patients
Multicenter, Phase III Study of Iodine-131 Tositumomab (Anti-B1 Antibody) for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin’s Lymphoma
T-Cell–Depleted Allogeneic Bone Marrow Transplant From HLA-Matched Sibling Donors for Non-Hodgkin’s Lymphoma
Consensus Statement on Prevention and Early Diagnosis of Lung Cancer
In Vivo Purging and Adjuvant Immunotherapy With Rituximab During PBSC Transplant For NHL
Fludarabine and Cyclophosphamide: A Highly Active and Well-Tolerated Regimen for Patients With Previously Untreated Indolent Lymphomas
Campath-1H Monoclonal Antibody in Therapy for Advanced Low-Grade Non-Hodgkin’s Lymphomas: A Phase II Study
AIDS Drugs Effective Against Most Common HIV Strain
Rituximab Therapy in Previously Treated Waldenström’s Macroglobulinemia: Preliminary Evidence of Activity
Related Videos
Some patients with large B-cell lymphoma may have to travel a great distance for an initial evaluation for CAR T-cell therapy.
Education is essential to referring oncologists manage toxicities associated with CAR T-cell therapy for patients with large B-cell lymphoma.
There is no absolute age cutoff where CAR T cells are contraindicated for those with large B-cell lymphoma, says David L. Porter, MD.
David L. Porter, MD, emphasizes referring patients with large B-cell lymphoma early for CAR T-cell therapy consultation.
It may be applicable to administer CAR T-cell therapy to patients with large B-cell lymphoma in a community or outpatient setting.
Related Content